Structuring Flow Cytometry Data for an AI-Ready Future
The webinar on June 24, 2025, presents new FCS Express features integrating with Dotmatics Luma to enhance flow cytometry data quality control, traceability, searchability, and cross-application integration, enabling researchers across disciplines to link and contextualize diverse experimental data for improved decision-making and an AI-ready future.
Flow cytometry is a key research method used in basic R&D, drug discovery, cell and gene therapy, and clinical diagnostics. The results from flow cytometry are often used to make key decisions that impact upstream and downstream experimental design and patient care across a variety of experimental modalities and disciplines.
Currently, there are few tools that enable linking and traceability from flow cytometry data to other domains such as antibody design, chemistry, sequencing, and statistics. Often, tools currently being used rely on unstructured, siloed data that is not easily shared across teams, departments, and locations.
This webinar introduces new functionality in FCS Express to support integration with Dotmatics Luma. Dotmatics Luma enables data from any experimental modality and data source to be joined together, providing click-button access for visualizations. This helps researchers make contextualized decisions across diverse teams, locations, and departments, and prepares data from a variety of sources for an AI-ready future state with data structuring.
Key topics include:
- Improving quality control, traceability, and integration of flow cytometry data
- Enhancing searchability and data reporting
- Facilitating cross-application integration
Featured Speakers:
- Phil Mounteney, Vice President of Science and Technology
- Sean Burke, President, De Novo Software
Event Details:
- Date: 24 June 2025
- Time: 12:00 PM EST
- Format: Virtual
Related
3 Customer Trends We’re Watching in 2025
In 2025, life science teams are prioritizing three key trends—Lab-in-a-Loop platforms that integrate instruments, data, workflows, and models to boost R&D efficiency; true multimodal discovery enabled by flexible informatics supporting diverse data types without fragmented tools; and Composite AI leveraging layered, governed, and traceable data across disciplines—all aimed at delivering tangible scientific innovation while addressing resource constraints and stringent AI governance requirements.
Insight Beyond Numbers: The Growing Significance of Visualizing Biological Data
The article emphasizes that data visualization is a critical and emerging subdiscipline in life sciences research, essential for interpreting complex, noisy, and interconnected biological data from advanced experimental techniques, enhancing understanding, communication, and collaborative innovation beyond mere aesthetics.
The Data Lifecycle: From Instrument Integration to Advanced Analysis
The article discusses how Dotmatics Luma™, a comprehensive scientific data platform, addresses the challenges faced by R&D teams in managing and integrating diverse, multimodal scientific data from instruments and various sources to streamline the entire data lifecycle—from ingestion and processing to advanced analysis—thereby enabling faster, AI-ready insights that accelerate innovation and research outcomes.
Dotmatics Mini-Summit: From Insights to Impact
The Dotmatics Mini-Summit: From Insights to Impact is a 90-minute digital event featuring CEO Thomas Swalla and experts demonstrating Dotmatics Luma, a no-code, multimodal data platform that automates aggregation of diverse research data from thousands of instruments and software, enables easy data modeling, streamlines scientific workflows, offers upcoming AI-powered natural language search, and supports FAIR data principles, followed by a live Q&A session.
Luma Antibody & Protein Engineering Solution for End-to-End Antibody Discovery
Dotmatics has launched the Luma Antibody & Protein Engineering Solution, the first in its Luma Multimodal R&D Solutions series, which integrates the Dotmatics Luma Scientific Intelligence Platform with key tools like Geneious, GraphPad Prism, and others to streamline and unify antibody discovery and development—particularly for monoclonal and multispecific antibodies—while supporting a broad range of therapeutic modalities including CAR-T, siRNA, ADCs, CRISPR, and vaccines within a collaborative, multimodal research environment.
Data Evolution in Pharma: The Spread of Multimodal
The pharmaceutical industry is shifting from single-mode to multimodal drug discovery, incorporating diverse therapeutic modalities like biologics, gene therapies, and small molecules, but this evolution presents significant challenges in integrating heterogeneous R&D data and technologies, necessitating advanced, compatible platforms to enable efficient collaboration and leverage AI-driven insights for faster, cost-effective drug development.